Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma

Overview of attention for article published in Frontiers in oncology, December 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 6 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 24,069 followers.

Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma https://t.co/KOwfw4TcPn https://t.co/0jQbqkPmvP

08 Dec 2022

Reply Repost Favourite

New research: Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma: Objective Results of Orient 15 indicated the… https://t.co/OGM

06 Dec 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.